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ABSTRACT
Organoids have extensive applications in many fields ranging from modelling 
human development and disease, personalised medicine, drug screening, etc. 
Moreover, in the last few years, several studies have evaluated the capacity of 
organoids as transplantation sources for therapeutic approaches and regenerative 
medicine. Nevertheless, depending on the origin of the cells and anatomical 
complications, an organoid transplant may make tissue regeneration difficult. 
However, some essential aspects of organoids including the morphological alterations 
and the growth pattern of the matched tumour and their healthy derived organoids 
have received less attention. Therefore, the current work focused on culturing 
matched healthy and tumour organoids from the same patient with colorectal cancer 
(CRC) and assessed their timed growth and structural differences on a daily basis. The 
healthy organoids underwent proliferation and branching morphogenesis, while the 
tumour organoids did not follow the same pattern, and the majority of them developed 
cystic structures instead. However, the number and size of tumour organoids were 
different from one patient to another. The differential morphological changes of the 
healthy versus human colonic tumour organoids likely linked to distinct molecular 
and cellular events during each day. Thus, while their specific structural features 
provide valuable in vitro models to study various aspects of human intestinal/colon 
tissue homeostasis and CRC which avoid or replace the use of animals in research, 
this model may also hold a great promise for the transplantation and regenerative 
medicine applications.
INTRODUCTION
Colorectal cancer (CRC) is the third most common 
malignancy in male and the second in the female 
worldwide with approximately 1.4 million new cases 
diagnosed in 2012 [1]. CRC ranks fourth in cancer-
related mortality among all malignancies in the world. 
The majority of the CRC tumours arise from benign 
precursors known as the adenoma, which develops into 
invasive carcinoma [2]. Variations in treatment response 
and cancer progression patterns between individuals 
may be due to the heterogeneity of CRC tumours, which 
defined as interactions of the genetic background of 
tumour bulk cells with their environment [3]. In fact, 
the differences in genetic and epigenetic properties of 
each cell and their correlated tumours, construct the 
level of this heterogeneity as a whole tumour. At the 
cellular level, the morphological features of cancer cells 
can be demonstrated based on specific antibodies and 
immunofluorescence staining, which allow researchers to 
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assess cellular events including cell proliferation, growth, 
differentiation, migration, and apoptosis within a tumour 
context. On the other hand, studying tumour diversity can 
be facilitated by the development of advanced models that 
closely resembles the in vivo tumour structure which may 
provide an alternative platform for the high-throughput 
studies and analysis. Therefore, in the last few years, a 
complex advanced 3-dimensional (3D) culture system 
known as organoids have been introduced as a model that 
mimics patients’ in vivo tissue in a variety of pathologic 
states [4–17].
The intestinal organoid as a 3D culture (which 
faithfully mimics the in vivo tissue from both intestinal 
crypts as well as single isolated Lgr5+ cells) was first 
established by Sato et al. [18, 19]. Several studies have 
since developed organoids from different mammalian 
organs [20–23]. Various essential exogenous growth 
factors and inhibitors are required to mimic the in vivo 
intestinal epithelial stem cell niche for the growth and 
expansion of organoids. These are including Wnt-3A, 
the Wnt agonist R-Spondin 1, the EGF and the BMP 
antagonist Noggin [18, 19, 24]. In recent years, many 
studies have conducted in culturing of the intestinal/colon 
organoids. To our knowledge, there are no systematic 
studies that communicate and compare the pattern of 
organoids growth/structure from normal and cancer-
adjacent tissue derived from one patient or comparison 
with another patient.
Herein, using the human colorectal tumour and 
adjacent healthy derived organoids of patients with CRC, 
we aimed to observe and evaluate the morphological 
alterations and the growth pattern between the two 
derived organoids from the same patient in vitro. Tumour 
and adjacent healthy tissue samples of seventeen patients 
with colorectal cancer collected from Nottingham Health 
Sciences Biobank (NHSB) [Queens Medical Centre, the 
University of Nottingham]. Based on our observations, the 
growth pattern and morphology of the organoids derived 
from colorectal cancer tumour and adjacent healthy 
tissues from the same patient differed significantly. 
Hence, studying this model of in vitro 3D organoid culture 
can potentially reduce or replace the use of animals in 
research and may also be beneficial in minimising the 
complications associated with particular physiological 
conditions upon transplantation, through their healthy 
growth in patient’s tissue.
RESULTS
Validation of conditioned media for organoid 
culture
To validate Wnt-3A, R-Spondin and Noggin 
conditioned medium, the TOP/FOP-flash luciferase 
reporter and Western blotting assays were carried 
out. The luciferase activity was significantly higher 
(P < 0.01) in cells treated with Wnt-3A together with 
R-Spondin (Supplementary Figure 1A), suggesting that 
these ligands can induce Wnt/β-catenin signalling in 
vitro. Furthermore, the western blotting analysis also 
confirmed the expression of the secreted Noggin protein 
in both monomer (32kD) and dimerised (64kD) forms 
[25] (Supplementary Figure 1B).
We had initiated our analysis by fixing and 
staining of organoids with the Phalloidin using of either 
whole mount sample or embedded paraffin sections 
[24]. Phalloidin functions by binding and stabilising 
filamentous actin (F-actin) (Supplementary Figure 2), 
but there was no any benefit to the live-imaging of an 
organoid with several focus levels forming a bright field 
stack, and by visualising the intensity variations of this 
stack using a phase contrast microscope. Thus, this study 
focused on the comparison of the two types of organoids 
using live organoids underlying the bright field and phase-
contrast microscopy.
Morphological changes of organoids derived 
from healthy colon epithelium
Upon seeding the isolated matched healthy colon 
crypts into the Matrigel, the organoid growth medium 
added, and the morphological changes imaged every 24 
hours (Figure 1). On day one post-culturing, the crypts 
underwent circumnavigating (Figure 1A) then the 
elongated intact crypt grown into multi-cell spheroids (also 
known as colonoids) in the following days. From days 2 
to 4, both crypts and colonoids possessed an enclosed 
central lumen and started budding into a new region with 
crypt-like structure (Figure 1B and 1C). The frequency 
of crypt budding increased rapidly during days 4 and 5 
and the colonoids underwent excessive expansion resulted 
in an increase in the size of the organoids, leading to the 
formation of new multicellular budding and branched 
structures. The central region of the organoids contained 
dead cells resembling the intestinal lumen. During days 
6-7, the mature organoids were either utilised for assays 
or further expanded in culture (Figure 1).
However, the continuous expansion of the organoids 
in culture for more than two weeks resulted in the 
formation of a very large mature organoid containing 
hundreds of crypt-villus like features, assembled both 
stem-cell and differentiated-cell compartments. Each of 
this crypt-villus like domains was capable of growing, 
budding, branching and formation of a new organoid, 
similar to the isolated crypt on the day zero (Figure 2). At 
this stage, these mature, healthy organoids can go under 
freezing methods for patient’s own organoid biobank 
maintenance. Off-The-Shelf organoids will be needed if 
organoid transplantation enters a clinical phase.
In this study, we established organoids from 
seventeen CRC-patients and identified their growth status 
and structure alterations by comparison to a matched 
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healthy organoids (Supplementary Table 1). However, 
under controlled conditions, it appeared that patients-
derived organoids were similar to those organoids isolated 
from five individual patients in most cases.
Morphological alterations of a colon cancer-
derived organoids
Unlike the adjacent healthy epithelium, no whole 
crypt-like structure observed in tumour samples at day 
zero, while some aggregated structures formed by a small 
population of cells (Figure 3). After seeding the tumour 
cells into Matrigel and adding organoid culture medium, 
a few cystic-like shape (representing the tumour derived 
organoids) with uneven borders appeared. In contrast to 
healthy organoids, these cystic-like structures failed to 
form budding or significant branching structures over 
a period of 4 to 14 days (Figure 3), possibly due to the 
deregulation of essential molecular and cellular signalling 
pathways required to maintain the colonic crypt proper 
Figure 1: Representative images of morphology alteration in healthy colon organoids. The left panel shows the gradual 
growth of organoids derived from the healthy human colon tissue adjacent to a tumour, day 0 to day 7. Scale bar, 250 μm. The remaining 
panels represent, the growth of healthy human colon-derived organoids from three different patients (P1, P2 and P3). Scale bar, 75 μm. 
The day zero crypts are representative images of cultured colonic crypts after seeding on the Matrigel, and it is not similar to the organoids 
showed for days 1 to 7. On day one, the crypt base region which enriched with stem cells started to grow (A). From day 2 to day 3, the 
continuous gradual growth of organoid resulted in the colonoids structure with few budding domains (B). On day 4, the top of the crypts 
sealed (C). On days 4 to 6, the developing crypt was actively grown and differentiated during branching. The central area (lumen) in 
organoids contained the dead cells. On day 7, further, expansion created mature organoids, comprising numerous new regions of crypt-
villus domains. Images in the first column captured by using a low magnification objective (1.25x) to focus mainly and to chase on 
the single/same type specimen for subsequent organoids growth. However, producing sharp and quality 3D images using lower than 
10x-magnification is very difficult. We have therefore used 10x objectives for columns 2 to 4.
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function [26]. Further, to evaluate and confirm the 
degree of heterogeneity of the individual organoids in 
corresponding to the heterogeneity of CRC, we re-cultured 
the 14 days organoids for further 7-10 days (Figure 4). 
These data suggest that the additional genetic defects/ 
changes or mechanisms intrinsic to cancer cells likely 
influence the organoid features.
To further investigate the extent of regenerative 
potential of tumour organoids upon on freeze-thawing 
and the abolition of canonical Wnt signalling, we re-
cultured the frozen organoids from patients one and two 
respectively. Interestingly, the tumour organoids were 
capable of growing and resulted in an increase in the 
number of buds/lobes from their original cystic shape 
bodies in a growth medium without Wnt-3A (Figure 5). A 
recent finding supports this observation that the activated 
Wnt signalling pathway promotes the colon tumour 
organoid formation in Wnt Niche-independent signalling 
[27], and the abolition of canonical Wnt signalling 
improved their differentiation potential [28]. Furthermore, 
to investigate whether organoids with a disrupted and 
dark morphology regions in the bright-field microscope 
represent dead cells, we performed live/dead staining 
assay. Here, we used Hoechst 33342 dye, a popular cell-
permeant nuclear counterstain for live-cell staining, and 
Propidium iodide (PI), which stain both viable cells and 
dead cells, on whole mount samples using both healthy and 
tumour organoids respectively (Figure 6). This data shows 
that the cell death responses and the number of dying 
cells in the healthy and tumour organoids are primarily 
different from each other. Also, a tumour crypt culture 
(days 4 to 14) possessed the cystic organoid structure with 
no cellular segregation and polarisation. The number of 
tumour cells capable of forming tumour organoids also 
varied from one patient to another. In some cases, very 
few tumour cells could grow into tumour organoid, while 
in other instances various tumour organoid structures were 
developed within a few days of seeding into the Matrigel. 
The observation indicates that not all the tumour cells of a 
bulk tumour are capable of generating tumour organoids. 
Moreover, the size of tumours-derived organoids was also 
different from the healthy-derived organoids (Figure 7). 
This data indicates that the structural features of a tumour 
derived organoids strongly mimic their tissue of origin.
Figure 2: Long-term expansion of healthy organoids. Growing the organoids over two weeks in culture steered the formation of a 
very large branched organoid compromising hundreds of crypt-villus domains. For details of branches in organoids, images captured with 
different focus lens. Scale bar, 75 μm. At this stage, the organoid can be broken apart, and single domain can be pooled in culture to form 
a new mature organoid, and it can be used to proceed the freezing process.
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DISCUSSION
The genotype and phenotype of CRC tumours and 
their adjacent healthy tissues are significantly different 
in vivo. To provide a better insight into these differences 
a sophisticated in vitro model is required. Such a model 
should allow the propagation of primary tumours and 
the adjacent healthy tissues in vitro while maintaining 
the whole genome, transcriptome, and proteome of the 
original materials. Over the last few years, the intestinal/
Figure 3: Representative images from patient-derived tumour organoids. The four above panels are representing the human 
colon-derived organoids with different magnifications. Scale bars, 75 μm and 25 μm. The left two panels show the morphological alterations 
of the first patient’ (P1) a tumour derived organoid at different magnifications during days 4 to 14. The right two panels show another 
patient’s derived tumour (P2) organoids grown and maintained for the same period. The lack of the intact crypt in tumour bulk is mainly 
due to the transformation of tumour cells as presented on day 0. Beside single cells, some other cells aggregated and formed clusters. 
Images in the first column, are captured by using a low magnification objective (1.25x) to focus mainly and to chase each specimen for 
subsequent organoids growth. However, producing sharp and quality 3D images using lower than 10x -magnification is very difficult. We 
have therefore used 10x objectives for columns 2 for each patient organoid.
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colonic organoids appeared as reliable 3D culture models 
to recapitulate the cellular and molecular features of the in 
vivo tissue growth.
Herein, we demonstrated the morphological 
changes of several tumours and their matched healthy 
tissues derived from CRC patients. The comparison 
of the morphology and growth pattern on daily bases 
indicated that both the tumours and adjacent healthy tissue 
obtained organoids possess fundamental difference in the 
phenotypical features, suggesting their molecular and 
genetic differences.
As previously reported, beyond 2-3 weeks, due to 
the consumption of growth factors and the subsequent 
induction of cell death, the old organoids display 
unhealthy state and activation of apoptotic processes. 
Therefore, these organoid cultures passaged, expanded 
and frozen. As a result, we have defined and described 
the organoid structures produced within 2-3 weeks in this 
study. It is of note that the tumour-derived organoids did 
not follow the similar growth pattern in all patients, likely 
due to differences in their age, genetic background, and 
medical history. Therefore, we cannot use organoids as a 
uniform tool across all patients; however, the improved 
methodology may highly increase the practicality of this 
model.
In the current study, the colon tumour and their 
adjacent healthy derived organoids were all grown in 
a similar shape and morphology presented in Figures 
1–3. In this model, both a tumour and adjacent derived 
organoids remarkably reflected the morphology of in 
vivo counterparts, indicating their advanced capability 
as a model to study CRC progression. In line with our 
observations, previous studies have also confirmed the 
reliability of an intestinal tumour and adjacent healthy 
derived organoids in cancer studies [26, 27].
These studies together support the development of 
personalised medicine approaches for CRC treatment. In 
this regard, Van de Wetering and colleagues generated an 
Figure 4: Long-term expansion of tumour organoids. Representative bright-field images of single 14 day’s tumour organoids from 
different patients that expanded in culture for further 7-10 days. Similar healthy organoids, the tumour organoids can develop for a long-
term, while cannot actively differentiate and show heterogeneous phenotypes and morphology. Scale bar, 75 μm.
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organoid biobank from 20 patients diagnosed with colon 
cancer [26]. Through the genomic analysis of a tumour 
and matched healthy derived organoids, they reported 
that organoids showed the main subtypes that exist in 
CRC tumours. Furthermore, they designed organoid 
drug screening platform for therapeutic compounds 
before going into a clinical trial on patients, highlighting 
their potential in personalised medical treatments 
[26]. Similarly, Fujii et al. also established a library of 
organoids from 55 human CRC tumours and 41 matched 
healthy tissues. They confirmed that the growth of 
tumour organoids is not dependent on exogenous niche 
components in the prevailing culture, as the Wnt signalling 
pathway activated in the majority of CRC tumours. These 
findings are consistent with our current results that tumour 
organoids can grow without activated Wnt signalling 
(Figure 5). They also revealed that the organoids were 
histopathologically similar to the transplanted tumours 
and origin tumours [27]. Moreover, Cristobal et al. 
recent study on transcriptome and proteome of organoids 
derived from a tumour and adjacent healthy tissue of seven 
patients with colon cancer revealed that the organoids 
retained the original characteristics of CRC tumours where 
originated [29].
The application of organoids for regenerative 
and transplantation studies has also been addressed in 
recent works [15, 17, 30–34]. In one study organoids 
derived from Lgr5+ stem cells were transplanted into 
the damaged mouse colon, where after one month, 
functional crypts were formed at the damaged zone, 
highlighting the promising capacity of the organoids in 
the transplantation studies [17]. Furthermore, using the 
CRISPR-Cas9 genome editing system, Schwank et al. 
were able to correct the deletion at position 508 of cystic 
fibrosis transmembrane conductor receptor (CFTR) with 
homologous recombination on intestinal organoid from 
patients with CF, providing a potential application of the 
engineered organoid for gene therapies and transplantation 
approaches [15]. Recently, an engineered human intestinal 
tumour transplanted orthotopically into a mice model to 
Figure 5: Tumour organoids growth in the presence and absent of Wnt-3A. Representative bright-field images of tumour 
organoids grown in the presence or absence of conditioned Wnt-3A. Images captured from patients 3 and 4 (P3 and P4), scale bars, 75 μm.
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study the colorectal tumour progression and metastasis has 
confirmed that the niche independency of distant tumours 
required the presence of at least four mutations [14].
On a broader scope, organoids hold a new hope 
in the area of regenerative medicine, particularly for 
organ transplantation purposes, where they can be used 
as a source of autologous tissue, avoiding the potential 
subsequent immune response and organ rejection upon 
transplantation [9]. However, an entirely successful 
transplantation could be difficult due to the limitations in 
the current delivery systems and the existing extracellular 
matrix (ECM) scaffolds such as Matrigel. Thus, more 
data are urgently needed on the reliability and validity 
of methods toward more reliable clinical or therapeutic 
practice. Such as the proper design of ECM and their 
compatibility with patients tissues [35], and the design of 
reliability studies in applying targeted delivery techniques 
like small molecules and expansion of organoids and graft 
survival [36]. Together, these studies have provided proof 
of concept for the regenerative and therapeutic utility of 
gut organoids and their promising future as a functional 
transplantable choice in different gastrointestinal (GI) 
diseases and injuries.
This study demonstrated for the first time, the 
morphological alterations in human colonic tumour 
and their matched healthy derived organoids, as all cell 
lineages can be fully differentiated, together with the 
above studies, represent a possible distinct molecular and 
cellular differences in their tissue of origin. Therefore, 
studying the organoid system will decisively contribute to 
the replacement and reduction of animal use. Furthermore, 
the growth of these organoids can be sensitised by 
changing culture conditions with growth factors/inhibitors, 
hence allowing investigation of multiple biological 
questions like cell cycle, apoptosis, cell signalling. These 
experiments are technically challenging to perform in 
a live animal, due to numerous inconveniences and 
physiologically variable parameters such as the route of 
administration and tissue distribution. Therefore becomes 
ethically costly as a large number of animals are required 
to have suitable statistical power for discovery science. 
Beyond these impacts, in principle, the development of 
Figure 6: Live/dead staining in expanded tumour and healthy organoids. Representative fluorescent images of organoids used 
for the analysis of cell death. Matrigel was disrupted mechanically and stained with a live/dead staining solution, contained Propidium 
iodide (PI) and Hoechst 33342 as outlined. Scale bars, 100 μm.
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Figure 7: Comparison of morphological alterations in human colon matched a tumour and healthy organoids. 
Differences in morphology and growth pattern of organoids derived from tumour/adjacent healthy tissue of patients with colon cancer 
within seven days implied the presence of different cellular and molecular process. Left panel represents the development of healthy 
colonic epithelium and middle panel indicates the growth pattern of a colonic tumour derived organoid. Scale bar, 75 μm. As the size of the 
tumour organoids was significantly smaller than their matched healthy samples on the same day, a higher magnification of a tumour derived 
organoid also showed (right panel, scale bar, 25 μm). In comparison to the healthy derived organoids, due to cell transformation and loss 
of differentiation activities, no intact crypt was detected in tumour mass after EDTA incubation. The growth pattern and size of a tumour 
derived organoids and their matched healthy tissue were significantly different with tumour organoids possess considerably a smaller size 
which slightly changed during the period.
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such a large number of colonoids that phenotypically 
screened may provide valuable tools to enhance organoid 
transplant for regenerative medicine.
MATERIALS AND METHODS
Isolation and culturing of human colonic crypts
Tumour and adjacent healthy tissue samples of 17 
patients with CRC collected from Nottingham Health 
Sciences Biobank (NHSB), Queens Medical Centre, 
University of Nottingham. Supplementary Table 1 shows 
the clinicopathological characteristics of patients enrolled 
in this study. A written informed consent was taken from 
each patient, and the local ethics committee approved 
the study protocol by the principles of the Helsinki 
Declaration. The tissue was washed with chilled PBS three 
times and cut into pieces of 5-10 mm. After incubation in 
25 ml EDTA solution (1 mM EDTA in PBS) at 4°C for 
40 minutes, the crypts were released from colon intestinal 
epithelium and subsequently collected. The crypts were re-
suspended in Matrigel at a concentration of approximately 
20 crypts/25 μL Matrigel. 25 μl crypt-containing Matrigel 
was carefully added to the centre of the well of a 48-well 
plate using chilled pipette tips. The plate was incubated 
at 37°C for 5 minutes to allow Matrigel to solidify. The 
Matrigel overlaid with 300-350 μL of complete organoid 
medium [18]. A 50 millilitre of complete medium 
supplemented with an advanced DMEM/F12, 50% of 
Wnt-, 20% of R-spondin-, 20% of Noggin- in-house 
conditioned media, 2% of B27 (x50, Invitrogen, 12587-
010), 125 μl of 1.25 mM n-Acetyl Cysteine (Sigma, 
A9165), 250 μl of 10 mM Nicotinamide (Sigma, 98-92-
0), 250 μl of EGF (100 μg/ml) (Sigma, E4127), 0.5 μM 
of A83-01 (TGF-β inhibitor, Tocris, 2939), 5 μl of 3 μM 
SB202190 (p38 inhibitor, Sigma, S7067) and 100 μg/ml of 
Primocin (InvivoGen, ant-pm-1).
Preparation of noggin-conditioned medium
Noggin is post-translationally modified protein 
and mainly secreted as a disulphide-bonded homodimer 
[37, 38]. A secreted noggin protein binds and inactivates 
members of the transforming growth factor-β 
(TGF-β) superfamily signalling proteins, such as bone 
morphogenetic protein-4 (BMP4). Analysis of mouse 
mutants shows that this interaction is essential to modulate 
the activities of bone morphogenetic protein (BMP) during 
development [39]. In human, a reduction in the amount of 
secreted dimeric Noggin accounts for the human skeletal 
phenotypes [38, 40].
In this study, the HEK293T cells [American Type 
Culture Collection (ATCC)] transfected with 15 μg of 
Noggin plasmid using Polyethylenimine (PEI) in Opti-
MEM (Thermo Fisher Scientific, 31985070). After 
transfection, the medium replaced with an advanced 
DMEM/F-12 (Invitrogen, 12634-028), supplemented with 
two mM L-glutamine, 100 U/ml Penicillin/Streptomycin 
(Pen/Strep) and ten mM HEPES (Invitrogen, 15630-122), 
and kept in the incubator for one week. After one week 
the medium was collected and centrifuged at 400 g for 4 
minutes and filtered by 0.22 μM filters. Then aliquoted 
and stored at -80°C. Western blotting assay validated the 
presence of Noggin as a secreted protein.
Western blotting
Western blotting performed as previously described 
by Li et al. [41]. An equal amount of total proteins 
denaturized, loaded into a 10% sodium dodecyl sulphate-
polyacrylamide gradient gel (SDS-PAGE) for separation 
and then transferred overnight to polyvinylidene fluoride 
(PVDF) membranes. Membranes were blocked with 3% 
bovine serum albumin (BSA) in Tris-buffered saline and 
probed with purified mouse anti-Noggin antibody (BD 
Biosciences).
Preparation of Wnt-3A- and R-Spondin 
1-conditioned media
HEK293T expressing R-Spondin 1 (HA-Rspo1-
Fc cell line) and HEK293T expressing an activated form 
of Wnt-3A (L-Wnt-3A cell line) received as a gift from 
Professor Hans Clevers (Hubrecht Institute, Netherlands). 
The Wnt-3A cell line was cultured in 20 ml of DMEM 
GlutaMAX supplemented with 10% FBS + Pen/Step 
and Zeocin (Thermo Fisher Scientific, R25001) (1.25 
μg/ ml). The flask was split into 6 × 175 cm2 flasks in 
growth medium with FBS, while the Zeocin added to 
only one container (for cell maintenance) and no Zeocin 
in the rest (5 × 175 cm2 flasks). Next, confluent cells 
were trypsinised, pooled in 600 ml growing medium 
(GlutaMAX) without Zeocin and plated in 30 × 150 cm2 
dishes for one week. Then, after one-week incubation, 
the medium harvested. The collected medium containing 
the Wnt-3A were centrifuged at 400 g for 4 minutes and 
passed through 0.22 μM filter. Then the medium was 
aliquoted in and stored in 50 ml tubes at 4°C. The HEK 
293T-HA-Rspo1-Fc cell line expressing R-Spondin 1 
(R-spo1) grown and the medium collected as previously 
described [24]. The activity of the Wnt-3A and R-Spondin 
1 (as a Wnt pathway agonist) was measured by TOP/FOP 
luciferase reporter assay.
Luciferase reporter assay
To evaluate the transactivation activity of Wnt-3A 
and R-Spondin 1 conditioned medium, TOP-flash/FOP-
flash dual luciferase reporter assay system (Promega 
#E1910) was exploited [42]. Also, Renilla luciferase 
(under SV40 constitutive active promoter) was used to 
normalise transfection efficiency. HEK293T cells were 
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seeded in triplicate into a 6-well plate (3 x 105 cells/well) 
and kept in the incubator overnight. When the cells were 
50-60% confluent, transfected with both Renilla luciferase 
vector (0.05 μg DNA/well) and, either TOP-flash or 
FOP-flash plasmids (0.2 μg DNA/well). The medium 
containing the transfection mixture was replaced with 
Wnt-3A + R-Spondin 1 conditioned media and left for 48 
hrs. Then, the medium discarded and the cells were lysed 
and prepared for the bioluminescence reading according 
to the Kit instructions. The bioluminescence produced 
was detected by a Luminoskan Ascent Microplate 
Luminometer (Thermo Fisher Scientific, UK). Also, the 
measurement of the Renilla luciferase activity done by 
adding 50 μl/well of Stop & Glo Reagent to the same 
wells. The Firefly luciferase readings were normalised to 
Renilla luciferase readings and then to the activity of the 
control samples. The significance of differences between 
the mean and the median was determined using the 
Student’s t-test and P < 0.05 (*) considered as significant.
Organoids live/dead staining
Cell death in organoids assessed by live/dead 
staining and subsequent fluorescence confocal microscopy. 
Matrigel was disrupted mechanically with a pipette tip 
and organoids were then transferred to an Eppendorf 
tube. Live organoids stained with 50 μg/ml Hoechst 
33342 (Sigma) and 50 μg/ml PI (Sigma) in the organoid 
medium. Organoids also fixed in 4% paraformaldehyde, 
washed with PBS, incubated with 100nM Alexa Fluor® 
488 Phalloidin and incubated for 60 min in the dark. Then 
microscopy was performed using the Leica DMI3000 B 
fluorescent microscope at x10 or x40 magnification.
Microscopy
The 3D organoids imaged at different zoom with 
objectives 1.25X, 5X, 10X and 40X using Leica DMI3000 
B Manual Inverted Microscope. Representative bright-
field images of organoids growths are across each day per 
group for three weeks in culture.
Supporting information
Supplemental Information contains Supplementary 
Figures 1 and 2, Legends and Supplementary Table 1, can 
be found with this article online at Oncotarget website.
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